Diabetes Mellitus, Type 1 Clinical Trial
— TAATOfficial title:
Evaluation of a Novel CGM Trend Arrow Adjustment Tool in Children & Adolescents With Type 1 Diabetes Using Insulin Pump Therapy and Continuous Glucose Monitoring (TAAT Study)
Continuous glucose monitoring (CGM) provides up to 288 blood glucose levels per day, updated
every 5 minutes and displayed in real-time on the insulin pump, which can be used to enhance
delivery of insulin through pump therapy. In addition this real-time CGM data includes
"trend arrows" which indicate when the blood glucose is rapidly falling or rising thus
enabling the pump user to make immediate adjustments in insulin delivery to prevent
subsequent low or high blood sugars. The trend arrows are displayed when the blood glucose
is rapidly falling or rising. For example, if the glucose is increasing by 1-2 mmol/L over
20 minutes, a single upward arrow alerts the pump wearer, who can then decide to give a
bolus of insulin or increase the meal bolus. Should the glucose level be increasing at a
rate greater than 2mmol/L over 20 minutes, 2 upward arrows are displayed and the user could
decide to give a larger bolus. The purpose of the bolus adjustment is to add insulin for the
predicted rise in glucose to prevent or reduce subsequent hyperglycemia. Similarly, a
decrease in the insulin bolus is advised if glucose levels are falling as evidenced by one
or two downward arrows.
However, effective strategies for adjusting insulin boluses based on CGM trend arrows are
lacking. The JDRF CGM Study Group recommended that boluses be adjusted based on trend arrows
using a standard 10-20% increase/decrease of the total original recommended bolus dose (10%
for one arrow up or down, and 20% for two arrows up or down), with the original bolus dose
calculated by the pump calculator (i.e. Bolus Wizard). However, the original recommended
bolus dose is dependent on the amount of food to be consumed (grams of carbohydrate) and the
current blood glucose (if above or below target range), as well as the amount of active
insulin, and therefore increasing or decreasing the total recommended bolus by 10-20% may
overcompensate for the trend arrows and result in postprandial hypoglycemia. Attempts to use
the10/20% formula within CHEO's large pediatric pump/CGM population resulted in low
acceptance and adherence by CGM users.
The CGM TIME Trial Study Group develop an innovative tool for adjusting boluses for CGM
trend arrows based on the patient's own insulin sensitivity factor (ISF). The Trend Arrow
Adjustment Tool formula is: if CGM shows a single arrow up or down: adjust bolus by +/-
(1.5/ISF) and for 2 arrows up or down +/- (3/ISF). Use of the Trend Arrow Adjustment Tool
within the CGM TIME Trial appears to lead to more appropriate adjustment in bolus dosing,
and more effective prevention of subsequent hyper- and hypoglycemia. Furthermore, this tool
appears to have excellent uptake amongst the TIME Trial participants, with observations that
there is continued usage of the tool throughout the 12 month study, and greater satisfaction
with this component of CGM. However, the tool has not been systematically evaluated.
The proposed study will evaluate the Trend Arrow Adjustment Tool, to determine its
effectiveness in reducing postprandial hyper- and hypoglycemia, as well as parent,
child/youth satisfaction, and ease of use of the tool based on self-report measures.
Comparison will be made with the 10/20% bolus adjustment & also to no adjustments to meal
boluses (i.e. ignoring CGM trend arrows). Should use of the Trend Arrow Adjustment Tool lead
to more time spent within the target glucose range, this will have immediate clinical
benefit for patients, including improved quality of life, and potentially a reduction in
HbA1c and prevention of long-term complications.
| Status | Completed |
| Enrollment | 20 |
| Est. completion date | May 2015 |
| Est. primary completion date | April 2015 |
| Accepts healthy volunteers | No |
| Gender | Both |
| Age group | 5 Years to 18 Years |
| Eligibility |
Inclusion Criteria: 1. Participants will be children and youth aged 5-18 years, attending CHEO diabetes clinic 2. Established Type 1 diabetes for more than 1 year, 3. Who have used an insulin pump and CGM for at least 3 months. 4. Willing to wear iPro2 blinded CGM and to use the Trend Arrow Adjustment Tool and the 10/20% bolus adjustment method. 5. Internet access at home (to upload CGM data). Exclusion Criteria: 1. Conditions which may interfere with the subject's ability to participate in the study. 2. Has received oral and/or intravenous steroid therapy (for any indication, at any dose and/or for any duration) on more than 2 separate occasions in the past 12 months. Use of inhaled and/or topical steroid therapy in the last 12 months does not exclude the subject |
Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment
| Country | Name | City | State |
|---|---|---|---|
| Canada | Children's Hospital of Eastern Ontario | Ottawa | Ontario |
| Lead Sponsor | Collaborator |
|---|---|
| Children's Hospital of Eastern Ontario | Juvenile Diabetes Research Foundation |
Canada,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Other | Uptake of Trend Arrow Adjustment Tool | Proportion of time the participants used the Trend Arrow Adjustment Tool to adjust the bolus | during 3 week study period | No |
| Other | Satisfaction/ease of use of Trend Arrow Adjustment Tool | Whether participants/parents were satisfied with Trend Arrow Adjustment Tool & if they would continue to use it/recommend to other families | during 3 week study period | No |
| Primary | Time spent with postprandial glucose level in target range | Glucose target level is 4-10mmol/L post meals | during 3 week trial | No |
| Secondary | Frequency & duration of postprandial hyperglycemia | Time spent with glucose above 10mmol/L post meals | during 3 week study period | No |
| Secondary | Frequency & duration of postprandial hypoglycemia | Time spent with glucose <3.9mmolL post meals | during 3 week study period | Yes |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04030091 -
Pulsatile Insulin Infusion Therapy in Patients With Type 1 and Type 2 Diabetes Mellitus
|
Phase 4 | |
| Terminated |
NCT03605329 -
Evaluation of the Severity of Cardiovascular Autonomic Neuropathy in Type 1 Diabetic Patients With OSAS
|
N/A | |
| Completed |
NCT01696266 -
An International Survey on Hypoglycaemia Among Insulin-treated Patients With Diabetes
|
||
| Recruiting |
NCT06050642 -
Study of the Impact of PROximity Support for Patients With Type 1 DIABetes Treated With an Insulin Pump or Closed Loop.
|
N/A | |
| Completed |
NCT05107544 -
Metabolic, Physical Fitness and Mental Health Effects of High Intensity Interval Training (HIIT) in Adolescents With Type 1 Diabetes
|
N/A | |
| Active, not recruiting |
NCT04443153 -
Adapting Diabetes Treatment Expert Systems to Patient in Type 1 Diabetes
|
N/A | |
| Completed |
NCT04569994 -
A Study to Look at the Safety of NNC0363-0845 in Healthy People and People With Type 1 Diabetes
|
Phase 1 | |
| Completed |
NCT04521634 -
Glycaemic Variability in Acute Stroke
|
||
| Completed |
NCT04089462 -
Effects of Frequency and Duration of Exercise in People With Type 1 Diabetes A Randomized Crossover Study
|
N/A | |
| Completed |
NCT03143816 -
Study Comparing Prandial Insulin Aspart vs. Technosphere Insulin in Patients With Type 1 Diabetes on Multiple Daily Injections: Investigator-Initiated A Real-life Pilot Study-STAT Study
|
Phase 4 | |
| Completed |
NCT01892319 -
An International Non-interventional Cohort Study to Evaluate the Safety of Treatment With Insulin Detemir in Pregnant Women With Diabetes Mellitus. Diabetes Pregnancy Registry
|
||
| Recruiting |
NCT04039763 -
RT-CGM in Young Adults at Risk of DKA
|
N/A | |
| Completed |
NCT04042207 -
Diabeloop for Highly Unstable Type 1 Diabetes
|
N/A | |
| Not yet recruiting |
NCT06068205 -
COMPARATIVE ANALYSIS OF THE MORPHO-MECHANICAL PROPERTIES OF RED BLOOD CELLS EXTRACTED FROM DIABETIC PATIENTS WITH AND WITHOUT MICROVASCULAR COMPLICATIONS
|
||
| Recruiting |
NCT05909800 -
Prolonged Remission Induced by Phenofibrate in Children Newly Diagnosed With Type 1 Diabetes.
|
Phase 2 | |
| Active, not recruiting |
NCT04974528 -
Afrezza® INHALE-1 Study in Pediatrics
|
Phase 3 | |
| Completed |
NCT04530292 -
Home Intervention and Social Precariousness in Childhood Diabetes
|
N/A | |
| Completed |
NCT05428943 -
OPT101 in Type 1 Diabetes Patients
|
Phase 1 | |
| Recruiting |
NCT03988764 -
Monogenic Diabetes Misdiagnosed as Type 1
|
||
| Completed |
NCT05597605 -
The SHINE Study: Safety of Implant and Preliminary Performance of the SHINE SYSTEM in Diabetic Subjects
|
N/A |